• Profile
Close

Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet’s disease

British Journal of Ophthalmology Sep 29, 2020

Keino H, Watanabe T, Nakayama M, et al. - Researchers conducted the study for assessing long-term effectiveness of infliximab (IFX) in refractory uveoretinitis associated with Behçet’s disease (BD) depending on uveoretinitis duration. Records of 16 patients with BD (32 eyes) followed for >5 years after starting IFX have been reviewed retrospectively. Long-term efficacy was contrasted between patients with short duration (≤ 18 months, n = 7) vs long duration (>18 months, n = 9) of their uveoretinitis prior to starting IFX. After starting IFX, the median follow-up was 132 months (76–146 months). The initiation of IFX therapy in BD patients within 18 months of their onset of uveoretinitis was more effective than after 18 months in maintaining good BCVA.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay